JUNE, 2022

Times
A monthly newsletter about everything "Telmisartan" and related

Latest News
about
Hypertension!
An exclusive read!

Bronchopulmonary Dysplasia (BPD) is a chronic lung disease requiring oxygen or

ventilator support; many antenatal and postnatal factors, and preterm birth,
affect BPD development. This meta-analysis was performed to examine the
association between maternal hypertension during pregnancy (HDP) and
neonatal bronchopulmonary dysplasia (BPD).

The diagnosis and follow-up of hypertension (HT) depend on the blood pressure
measurements, which can be affected by several factors. This study aims to
explore the role of uric acid/HDL-cholesterol ratio (UHR) in HT and whether/or not
it was associated with poor blood pressure control.

ARBs as anti-hypertensive agents are the most common component of dual and
triple therapies in India. Telmisartan, an ARB is mostly preferred because of its
continual effectiveness, morning BP surge control, and prevention of
microalbuminuria, nephropathy, cardiovascular morbidity, and mortality.
Therefore this clinical data analysis of telmisartan was conducted for
hypertension management in the Indian population.

Fixed-dose combination (FDC) therapies are being increasingly recommended for

the initial or early management of patients with hypertension, as they reduce
treatment complexity and therapeutic inertia. This study investigated the
association of antihypertensive triple-drug FDC therapy with therapeutic inertia
and prescribing patterns compared with usual care.
Association of Maternal Hypertensive Disorders During
Pregnancy With Severe Bronchopulmonary Dysplasia: A
Systematic Review and Meta-Analysis
(Adapted from: Lim, Gina et al., Journal of Korean medical science vol. 37,16 e127. 25 Apr. 2022.)

Aim of the review:

This Meta-analysis aims to examine the association between maternal hypertension
during pregnancy (HDP) and neonatal bronchopulmonary dysplasia (BPD).
Recent findings:
Maternal HDP was not significantly associated with BPD, defined as an oxygen
dependency at 36 weeks of gestation (OR, 1.162; 95% CI, 0.991–1.362; P = 0.064)
Maternal HDP was significantly associated with severe BPD (OR, 2.341; 95% CI,
1.726–3.174; P < 0.001)
An association between HDP severity and BPD was reported, but the duration of
ventilator support and oxygen administration is likely to vary by the clinician and
medical unit.

Meta-analysis of the relationship

between maternal pre-
eclampsia and neonatal
bronchopulmonary dysplasia
defined as an oxygen
requirement at 28 days of
postnatal age.
HDP = hypertension during pregnancy, CI =
confidence interval.

In conclusion, no association was found between maternal HDP and neonatal BPD
other than severe BPD. Further studies are required to evaluate the relationships
between HDP onset and/or changes in the levels of HDP-associated anti-angiogenetic
and angiogenic factors with neonatal BPD.

Poorly controlled hypertension is associated with elevated

serum uric acid to HDL-cholesterol ratio: a cross-sectional
cohort study
(Adapted from: Aktas, Gulali et al. Postgraduate medicine vol. 134, no. 3, April 2022, pp. 297-302.)

Aim of the review:

This study aims to explore the role of uric acid/HDL-cholesterol ratio (UHR) in HT and
whether/or not it was associated with poor blood pressure control.

How was the study done:

This retrospective cross-sectional cohort study consisted of 535 subjects; 258 in the
well-controlled hypertension group, 186 in the poorly controlled hypertension group,
and 91 in the control group. Median uric acid/HDL-cholesterol ratio (UHR) levels of the
poorly controlled HT group (13 (4-43) %) were significantly higher than well-controlled
HT group 11 (4-22) %) and control group (8 (4-19) %) (p < 0.001). UHR was an
independent risk factor for poor BP control in HT subjects, and a unit elevation in UHR
increased the risk of poorer BP control by 7.3 times (p < 0.001, 95%CI: 3.9-13.63).

Assessment of UHR may be useful in HT patients since elevated UHR levels could be
associated with poor blood pressure control in this population.
Clinical data analysis of telmisartan for hypertension
management in Indian population
(Adapted from: Kumar et. al. “Clinical Data Analysis of Telmisartan for Hypertension Management in Indian Population.”
Bioinformation, vol. 17, no. 6, June 2021, pp. 652–59

Aim of the study:

Telmisartan is the most preferred ARB due to its continual effectiveness, control of
morning BP surges, prevention of microalbuminuria, nephropathy, and cardiovascular
disease morbidity. Thus, it is important to conduct clinical data analysis of telmisartan for
hypertension management in the Indian population.

Key Findings:
The excess salt intake (39.0%) was the most common risk factor.
Analysis of the patient compliance suggested that 98.4% of patients were compliant,
and 97.6% of patients achieved the target BP goal with telmisartan-based therapy.
Telmisartan is efficacious and tolerable for BP control when used as part of monotherapy
and in combination therapy for Indian patients.
This is effective irrespective of age, duration, and stages of Hypertension. Telmisartan is
shown to provide optimal cardioprotection along with a good tolerance profile.

Mean SBP and DBP significantly

decreased after treatment

Association of Low-Dose Triple Combination Therapy with Therapeutic

Inertia and Prescribing Patterns in Patients with Hypertension: A
Secondary Analysis of the TRIUMPH Trial
(Adapted from: Wang, Nelson, et al. “Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and
Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.” JAMA Cardiology, vol.
5, no. 11, Nov. 2020, p. 1219)

Aim of the study:

This study investigates the association of antihypertensive triple-drug FDC therapy
(telmisartan, 20 mg; amlodipine, 2.5 mg; and chlorthalidone, 12.5 mg) with therapeutic
inertia and prescribing patterns compared with usual care.
How was the study done:
700 patients with mild to moderate Hypertension were randomized to a once-daily FDC
pill. Therapeutic inertia, is defined as not intensifying therapy in those with blood
pressure (BP) above target. Prescribing patterns were characterized by BP-lowering drug
class and treatment regimen potency

During follow-up, there was a large

reduction in the number of unique
BP-lowering drug regimens in the
triple pill group compared with the
usual care group

Triple pill FDC therapy substantially simplified prescribing patterns and improved 6-
month BP control rates compared with usual care.
Rates of therapeutic inertia were significantly different between those in the triple pill
group and those in the usual care group at the week 6 visit 86.8% vs. 63.9% and the week
12 visit 90% vs. 64.8% respectively.
Significantly more patients (69.5%) in the triple pill group achieved blood pressure targets
compared with those in the usual care group (55.3%).
 Conference Details
31st European Meeting on
Hypertension and Cardiovascular
Protection
It will be held on June 17-20, 2022, in Athens,
Greece. The annual European Hypertension
Meetings offer the highest quality scientific
programs related to research in Basic and
Clinic areas in Hypertension with State-of-
the-Art Lectures, Satellite Symposia, Teaching
Sessions, and credits for qualifying as
Hypertension Specialists of the European
Society of Hypertension.
https://www.eshonline.org/meetingsevents/a
nnual-meeting/
26th Annual Hypertension,
Diabetes & Dyslipidemia
Conference
It is a day-intensive conference held on June
23-25, 2022, in Charleston, South Carolina,
addressing all the issues confronting
clinicians who treat challenging patients with
diabetes, hypertension, and dyslipidemia .
The participant will learn the most current
information on these issues and will be able
to apply these important clinical principles
back to their everyday practice to improve
the care of their patients.
https://www.cmemeeting.org/cme-
conferences/charleston-south-carolina-cme
The PHA International Conference
and Scientific Sessions
It will be held on June 10-12, 2022, in Atlanta.
It is the world's largest gathering of people
with pulmonary hypertension (PH), caregivers,
and health care professionals. PHA 2022,
PHA's 15th conference, will take place in
Atlanta, with the theme "PHacing the Future
Together." Those who can't attend in person
can register for live-streamed conference
highlights.
In Hypertensives with CV risk
In newly diagnosed hypertensives
PHA conferences have offered patients and
families opportunities to participate in PH
research studies ever since the first
conference in 1994.
https://na.eventscloud.com/website/31753/
10th International Conference on
Hypertension and Healthcare
It will be held on June 13-14, 2022 Madrid,
Spain. The theme of this conference is:
"Exploring the new horizons to cure
Hypertension and Cardiac Health."
Hypertension 2022 will be a platform for all
scientists, world-class professors and
cardiologists, nephrologists, endocrinologists,
psychiatrists, osteopathicians, bariatrics,
nurses, and healthcare professionals to
discuss an approach for hypertension and
diagnosis treatment and prevention of
elevated blood pressure.
https://hypertension.europeannualconference
s.com/
2nd Global Conclave on
Hypertension and Healthcare Expo
2nd Global Conclave on Hypertension and
Healthcare Expo will be held on June 15-16,
2022, in London, UK. The conference mainly
runs on the theme: "Cure Hypertension: take
Control of your life," which brings together the
brightest and most prolific minds to discuss
the interesting concepts of Hypertension and
Healthcare diagnosis and management using
the modern techniques at Euro Hypertension
2022.
https://hypertension.annualcongress.com/
GGI-CO-A1-AQS-300025817-LL-E22-0657